Vaccines
Vaccines contain antigenic substances capable of inducing immunity against an infective agent or toxin.
They are frequently administered prophylactically but are increasingly being researched and developed in a therapeutic context (eg cancer vaccines which are designed to equip a patient’s immune system to treat an existing cancer).
While the global market for vaccines is less than 3% of the total pharmaceuticals market, World Health Organization research suggests that over the next few years, the vaccine market will enjoy a growth rate of 10% to 15% per year versus the 5% to 7% seen in the overall market.
To take a share of this expanding market, companies must navigate a number of challenges. The assessment, licensing and control of vaccines (which are biological medicinal products) occurs in an environment of rapid innovation and complex quality concerns. Our deep experience of vaccines, combined with the fact that our team includes lawyers with degrees in relevant scientific areas (molecular biology, biochemistry, genetics etc), enables us to quickly grasp evolving issues and technical concepts and provide nuanced and tailored advice.
We are trusted by many of the world’s leading vaccine companies to help them navigate all stages of the vaccine lifecycle.
Explore our sectors
News and insights
Publications: 20 March 2024
Allen & Overy’s Nicole Daley on the rebound in M&A activity in the pharma industry
Nicole Daley, life sciences and M&A partner at Allen & Overy, discussed the steady pickup in M&A in the pharma industry after years of underperformance with PharmaVoice.
Publications: 13 March 2024
Abuse of dominance enforcement declines as new forums emerge
The level of fines imposed in abuse of dominance cases continued to decrease across the world in 2023.
Blog Post: 20 June 2022
Breaking: Global Covid-19 IPR waiver approved
Last Friday 17 June 2022, the WTO member states came to an agreement on the long negotiated TRIPS Waiver. In its annual 6 days conference (the Ministerial Conference), the WTO member states agreed…
Blog Post: 03 May 2022
Potential compromise on Covid-19 IPR waiver: deadlock resolved?
Last month, a leaked document regarding the TRIPS Waiver revealed a breakthrough between the EU, South Africa, India and the United States. After 18 months of negotiations, the four parties now have…